IN8bio, Inc. Common Stock

INABNASDAQ • USD
0.82 USD
↘ 0.00 (0.49%)AT CLOSE (03:59 PM EST)
0.80
↘ 0.02 (1.96%)
POST MARKET (AS OF 07:56 PM EST)
Post Market
AS OF 07:56 PM EST
0.80
↘ 0.02 (1.96%)
🔴Market: CLOSED

IN8bio, Inc. Common Stock (INAB) trades at $0.82 per share. Technical and fundamental signals converge bearish — technicals rate "Strong Sell" while fundamentals read "Sell". Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.

Technical & fundamental data as of Nov 16, 2026.

Open?$0.83
High?$0.93
Low?$0.72
Prev. Close?$0.82
Volume?5.1M
Avg. Volume?203.3K
VWAP?$0.88
Rel. Volume?25.03x
Bid / Ask
Bid?$0.75 × 1.3K
Ask?$0.89 × 100
Spread?$0.14
Midpoint?$0.82
Valuation & Ratios
Market Cap?8.9M
Shares Out?10.8M
Float?7.0M
Float %?71.4%
P/E Ratio?N/A
P/B Ratio?0.63
EPS?-$1.80
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
Employees
20
Market Cap
8.9M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed
2021-07-30
Address
EMPIRE STATE BUILDING
NEW YORK, NY 10118
Phone: (646) 600-6438
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
77
Short Sent.?
80
Piotroski F-Score?0/9Weak
Altman Z-Score?-13.19Distress
Confidence?43%Low
Full Fundamental Analysis →
Short InterestLow
Short % of Float?0.22%Low
Short Interest?15.7K
Days to Cover?1.0
Free Float7.0M
Avg Daily Volume36.2K
Settlement Date2026-10-30
Financial Health
Current Ratio?5.78Strong
Quick Ratio?5.78Strong
Cash Ratio?5.32Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
97
0.63CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
Peers
100
S&P
97
0.3CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-136.9%WEAK▾
ROA?
S&P
3
-103.8%WEAK▾
Cash Flow & Enterprise
FCF?$-14999000
Enterprise Value?$-5046201
Fundamentals ratios updated end of day